Rocky Mountain Bio/Medical Conversion and Commercialization Project

DMR-9413093， PI-Kontnik：该项目由技术再投资项目（TRP）的技术部署活动领域支持，旨在从多个来源识别、提取和转换生物医学技术。目标包括帮助国防公司了解多元化的机会，并帮助有限的公司真正走上多元化的商业道路。其中一些公司将被纳入现场孵化器。该项目将与美国国立卫生研究院、科罗拉多先进技术研究所和科罗拉多研究型大学密切协调。它将建立在与包括马丁·玛丽埃塔（Martin Marietta）在内的多家目标公司的既定关系之上。TRP的目标是刺激向不断增长的、综合的、国家工业能力的过渡，提供最先进、最经济的军事系统和最具竞争力的商业产品。TRP计划旨在扩大美国商业和两用领域的高质量就业机会。并明显提高了美国的竞争力。的竞争力。这是通过应用国防和商业资源来开发军民两用技术，向小企业提供制造和技术援助，以及提高美国国防和商业能力的教育和培训项目来实现的。制造技能和目标是流离失所的国防工业工人。这个具体的项目将使科罗拉多州的一些国防公司进入生物医学产品领域，从而使他们的产品基础多样化，进入非国防领域

DMR-9413093, PI-Kontnik: This project, supported under the Technology Deployment activity area of the Technology Reinvestment Project (TRP), is designed to identify, extract and transition biomedical technologies from a number of sources. The goals include helping defense firms understand the opportunities for diversification, and assisting a limited number of firms to actually embark on a business course of diversification. Some of these firms will be incorporated into an on-site incubator. This project will be coordinated closely with the National Institutes of Health, the Colorado Advanced Technology Institute, and the Colorado research universities. It will build on established relationships with a number of target companies, including Martin Marietta. ***The objective of the TRP is to stimulate the transition to a growing, integrated, national industrial capability which provides the most advanced, affordable, military systems and the most competitive commercial products. TRP programs are structured to expand high quality employment opportunities in commercial and dual-use US. industries and demonstrably enhance US. competitiveness. This is accomplished through the application of defense and commercial resources to develop dual-use technologies, manufacturing and technology assistance to small firms, and education and training programs that enhance US. manufacturing skills and target displaced defense industry workers. This specific project will enable a number of defense-based companies in Colorado to enter the biomedical product arena, thereby allowing them to diversify their product base into the non-defense sector.***